An inhibitor of Wnt signaling
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Adavivint

Item No. 43927

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
N-[5-[3-[7-(3-fluorophenyl)-3H-imidazo[4,5-c]pyridin2-yl]-1H-indazol-5-yl]-3-pyridinyl]-3-methyl-butanamide
CAS Number
1467093-03-3
Synonyms
  • Lorecivivint
  • SM-04690
Molecular Formula
C29H24FN7O
Formula Weight
505.6
Purity
≥98%
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
DMSO: Slightly soluble: 0.1-1 mg/ml
SMILES
O=C(CC(C)C)NC1=CC(C2=CC3=C(C=C2)NN=C3C4=NC5=C(N4)C(C6=CC(F)=CC=C6)=CN=C5)=CN=C1
InChi Code
InChI=1S/C29H24FN7O/c1-16(2)8-26(38)33-21-10-19(12-31-13-21)17-6-7-24-22(11-17)28(37-36-24)29-34-25-15-32-14-23(27(25)35-29)18-4-3-5-20(30)9-18/h3-7,9-16H,8H2,1-2H3,(H,33,38)(H,34,35)(H,36,37)
InChi Key
AQDWDWAYVBQMAM-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $28

    Add

    5 mg

    $116

    Add

    10 mg

    $152

    Add

    25 mg

    $241

    Add
    Kinase Resource Center
    Discover Products & Resources for Kinase Research
    • Kinase inhibitors, screening libraries, assay kits, & more
    • Tools to study kinase signaling pathways:
      • Growth factor signaling
      • PI3K/Akt/mTOR
      • MAPKs (ERK, p38, & JNK)
      • JAK/STAT signaling
    • Articles, resources, & advice
    EXPLORE NOW
    Product Description

    Adavivint is an inhibitor of Wnt signaling (EC50 = 19.5 nM in a reporter assay using SW480 cells).1 It inhibits CMGC family kinases, including CDC-like kinase 2 (Clk2) and dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A; IC50s = 7.8 and 26.9 nM, respectively), as well as Clk1, Clk3, Clk4, DYRK1B, glycogen synthase kinase 3β (GSK3β), and homeodomain-interacting protein kinase 1 (HIPK1), HIPK2, and HIPK3 (IC50s = 16.8-239 nM).2 Adavivint also induces activation of YES-associated transcriptional regulator (YAP) in a reporter assay using HEK293A cells (EC50 = 1.2 nM) in a Clk2-dependent manner.3 It induces chondrogenesis in primary human bone marrow-derived mesenchymal stem cells (MSCs).1 Adavivint inhibits the replication of pseudorabies virus in infected HeLa, BHK-21, Vero, and PK(15) cells (IC50s = 0.16, 0.19, 0.22, and 0.35 µM, respectively).4 Intra-arterial administration of adavivint (0.3 µg/animal) decreases disease severity in a surgically induced rat model of osteoarthritis.1 Adavivint (50 mg/kg) also inhibits tumor growth in a patient-derived organoid xenograft mouse model of colorectal cancer.5

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Deshmukh, V., Hu, H., Barroga, C., et al. A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage 26(1), 18-27 (2018).

    2. Deshmukh, V., O'Green, A.L., Bossard, C., et al. Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment. Osteoarthritis Cartilage 279(9), 1347-1360 (2019).

    3. Bulos, M.L., Grzelak, E.M., Li-Ma, C., et al. Pharmacological inhibition of CLK2 activates YAP by promoting alternative splicing of AMOTL2. bioRxiv [Preprint] 1-17 (2023).

    4. Wang, C., Wang, T., He, Q., et al. Inhibition of the canonical Wnt/β-catenin pathway interferes with macropinocytosis to suppress pseudorabies virus proliferation. Vet. Microbiol. 301, 110373 (2025).

    5. Xiang, Z., Wang, Y., Ma, X., et al. Targeting the NOTCH2/ADAM10/TCF7L2 axis-mediated transcriptional regulation of Wnt pathway suppresses tumor growth and enhances chemosensitivity in colorectal cancer. Adv. Sci. (Weinh) 12(3), e2405758 (2025).